Press Releases

Year

November 8, 2018

Osmotica Pharmaceuticals plc Reports Third Quarter 2018 Results

BRIDGEWATER, N.J. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2018 .

November 5, 2018

Osmotica Pharmaceuticals plc to Discuss Third Quarter 2018 Financial Results on November 8, 2018

BRIDGEWATER, N.J. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2018 third quarter financial results on Thursday, November 8, 2018 , after

October 22, 2018

Osmotica Pharmaceuticals plc Announces Closing of Initial Public Offering

BRIDGEWATER, N.J., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, today announced the closing of its initial public offering of 7,647,500 ordinary shares at a public offering price of $7.00 per share.

October 17, 2018

Osmotica Pharmaceuticals plc Announces Pricing of Initial Public Offering

BRIDGEWATER, N.J., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, today announced the pricing of its initial public offering of 6,650,000 ordinary shares at a public offering price of $7.00 per share.

February 19, 2018

FDA Approves Osmotica Pharmaceutical’s Once-Daily OSMOLEX ER™ (amantadine) extended-release tablets for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions in Adults

Investor Relations

News

Press Releases

Press Releases

Press Releases